loading
Precedente Chiudi:
$8.87
Aprire:
$8.97
Volume 24 ore:
298.16K
Relative Volume:
1.09
Capitalizzazione di mercato:
$414.91M
Reddito:
$36.90M
Utile/perdita netta:
$-166.28M
Rapporto P/E:
-2.5289
EPS:
-3.29
Flusso di cassa netto:
$-203.53M
1 W Prestazione:
-0.60%
1M Prestazione:
+18.86%
6M Prestazione:
+27.41%
1 anno Prestazione:
-66.77%
Intervallo 1D:
Value
$8.30
$9.0998
Intervallo di 1 settimana:
Value
$7.80
$9.1592
Portata 52W:
Value
$6.10
$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name
Nome
Bicycle Therapeutics Plc Adr
Name
Telefono
011441223261503
Name
Indirizzo
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Name
Dipendente
305
Name
Cinguettio
@Bicycle_tx
Name
Prossima data di guadagno
2025-08-08
Name
Ultimi documenti SEC
Name
BCYC's Discussions on Twitter

Confronta BCYC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BCYC
Bicycle Therapeutics Plc Adr
8.32 614.75M 36.90M -166.28M -203.53M -3.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.79 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.46 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.63 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
796.92 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.10 36.88B 4.56B -176.77M 225.30M -1.7177

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-08 Iniziato Stephens Equal-Weight
2024-09-06 Iniziato RBC Capital Mkts Outperform
2024-08-07 Downgrade B. Riley Securities Buy → Neutral
2023-09-11 Aggiornamento B. Riley Securities Neutral → Buy
2022-08-31 Iniziato Cowen Outperform
2022-07-28 Iniziato Barclays Overweight
2022-07-06 Ripresa Canaccord Genuity Buy
2022-04-13 Downgrade B. Riley Securities Buy → Neutral
2022-04-07 Ripresa Cantor Fitzgerald Overweight
2022-02-14 Iniziato Morgan Stanley Equal-Weight
2021-12-17 Iniziato SVB Leerink Outperform
2021-12-09 Iniziato Needham Buy
2021-09-30 Iniziato B. Riley Securities Buy
2021-04-20 Iniziato JMP Securities Mkt Outperform
2020-10-12 Iniziato Cantor Fitzgerald Overweight
2020-06-12 Iniziato Oppenheimer Outperform
2020-04-17 Iniziato H.C. Wainwright Buy
2019-11-14 Iniziato ROTH Capital Buy
2019-09-11 Aggiornamento Goldman Neutral → Buy
2019-06-17 Iniziato Canaccord Genuity Buy
2019-06-17 Iniziato Goldman Neutral
2019-06-17 Iniziato Jefferies Buy
2019-06-17 Iniziato Piper Jaffray Overweight
Mostra tutto

Bicycle Therapeutics Plc Adr Borsa (BCYC) Ultime notizie

pulisher
Oct 12, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 12, 2025
pulisher
Oct 10, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 10.5%What's Next? - MarketBeat

Oct 10, 2025
pulisher
Oct 06, 2025

Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 3,231 Shares - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 2,263 Shares of Stock - MarketBeat

Oct 06, 2025
pulisher
Oct 03, 2025

Bicycle Therapeutics Sees Unusually Large Options Volume (NASDAQ:BCYC) - Defense World

Oct 03, 2025
pulisher
Oct 02, 2025

Stock Traders Purchase High Volume of Bicycle Therapeutics Call Options (NASDAQ:BCYC) - MarketBeat

Oct 02, 2025
pulisher
Sep 29, 2025

Goldman Sachs Group Inc. Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World

Sep 29, 2025
pulisher
Sep 24, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 7.8%Here's Why - MarketBeat

Sep 24, 2025
pulisher
Sep 22, 2025

126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Acadian Asset Management LLC - MarketBeat

Sep 22, 2025
pulisher
Sep 20, 2025

Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $22.22 - MarketBeat

Sep 20, 2025
pulisher
Sep 18, 2025

126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Bought by Acadian Asset Management LLC - Defense World

Sep 18, 2025
pulisher
Sep 17, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Sep 17, 2025
pulisher
Sep 11, 2025

Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World

Sep 11, 2025
pulisher
Sep 09, 2025

Bicycle Therapeutics appoints oncology veterans Dansey and Hoppenot to board - Investing.com India

Sep 09, 2025
pulisher
Sep 06, 2025

Caption Management LLC Sells 81,517 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 06, 2025
pulisher
Sep 05, 2025

Armistice Capital LLC Has $22.69 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 05, 2025
pulisher
Sep 04, 2025

Long Focus Capital Management LLC Acquires 750,661 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 04, 2025
pulisher
Sep 03, 2025

Bicycle Therapeutics PLC Sponsored ADR $BCYC Stock Holdings Cut by Tybourne Capital Management HK Ltd. - MarketBeat

Sep 03, 2025
pulisher
Aug 29, 2025

Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025 - GlobeNewswire Inc.

Aug 29, 2025
pulisher
Aug 27, 2025

Candriam S.C.A. Acquires 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Aug 27, 2025
pulisher
Aug 20, 2025

Analysts’ Weekly Ratings Updates for Bicycle Therapeutics (BCYC) - Defense World

Aug 20, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress By Investing.com - Investing.com South Africa

Aug 13, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Given New $13.00 Price Target at Morgan Stanley - Defense World

Aug 13, 2025
pulisher
Aug 08, 2025

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - Placera.se

Aug 08, 2025
pulisher
Aug 01, 2025

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN

Aug 01, 2025
pulisher
Jul 31, 2025

Rice Biotech Launch Pad adds TPG Life Sciences’ Carolyn Ng to board - Investing.com

Jul 31, 2025
pulisher
Jul 29, 2025

Coursera (NYSE:COUR) Sees Strong Trading Volume on Analyst Upgrade - Defense World

Jul 29, 2025
pulisher
Jul 17, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

William Blair Brokers Decrease Earnings Estimates for TLX - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Purchases 5,315 Shares of Aaron’s Holdings Company, Inc. (NYSE:PRG) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Raises Stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) - Defense World

Jul 17, 2025
pulisher
Jul 04, 2025

The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World

Jul 04, 2025
pulisher
Jun 22, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World

Jun 22, 2025
pulisher
May 07, 2025

Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX

May 07, 2025
pulisher
May 01, 2025

Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa

May 01, 2025
pulisher
Apr 24, 2025

How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN

Apr 23, 2025
pulisher
Apr 23, 2025

Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com

Apr 23, 2025
pulisher
Apr 07, 2025

Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 07, 2025
pulisher
Apr 05, 2025

Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India

Apr 05, 2025

Bicycle Therapeutics Plc Adr Azioni (BCYC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Bicycle Therapeutics Plc Adr Azioni (BCYC) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Lee Kevin
CHIEF EXECUTIVE OFFICER
Oct 02 '25
Sale
8.40
2,263
19,009
478,541
Skynner Michael
CHIEF TECHNOLOGY OFFICER
Oct 03 '25
Sale
8.41
978
8,225
118,277
Skynner Michael
CHIEF TECHNOLOGY OFFICER
Oct 02 '25
Sale
8.40
824
6,922
119,255
Milnes Alistair
CHIEF OPERATING OFFICER
Oct 02 '25
Sale
8.40
1,147
9,635
94,355
Milnes Alistair
CHIEF OPERATING OFFICER
Oct 03 '25
Sale
8.41
978
8,225
93,377
Hannay Michael Charles Ferguso
CHIEF PROD & SUPPLY CHAIN OFF
Oct 02 '25
Sale
8.40
473
3,973
53,352
Hannay Michael Charles Ferguso
CHIEF PROD & SUPPLY CHAIN OFF
Oct 03 '25
Sale
8.41
250
2,102
53,102
Young Alethia
Chief Financial Officer
Oct 02 '25
Sale
8.51
482
4,103
44,704
Thompson Travis Alvin
CHIEF ACCOUNTING OFFICER
Oct 02 '25
Sale
8.40
221
1,856
31,300
Thompson Travis Alvin
CHIEF ACCOUNTING OFFICER
Oct 03 '25
Sale
8.41
103
866
31,197
$21.35
price down icon 5.74%
$83.80
price down icon 1.12%
$31.81
price down icon 0.13%
$102.06
price down icon 2.32%
$162.33
price down icon 1.26%
biotechnology ONC
$320.10
price down icon 4.68%
Capitalizzazione:     |  Volume (24 ore):